Navigation Links
MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results
Date:5/3/2011

fiscal 2011 full year operating expenses, excluding non-cash charges such as stock-based compensation and depreciation, to be approximately $50 to $55 million. In addition, the Company currently anticipates capital expenditures in 2011 to be approximately $4 to $5 million. As previously disclosed, the Company anticipates loan payments of approximately $8 million in 2011 related to a working capital loan. Collaboration revenues are estimated to be approximately $65 million in 2011. This estimate includes amortization of the upfront payment received in February 2011 and a milestone payment that the Company would be eligible to receive in 2011 under its collaboration agreement with Allergan, if a certain milestone is met.

About MAP PharmaceuticalsMAP Pharmaceuticals is an emerging biopharmaceutical company focused on developing and commercializing new therapies to address undermet patient needs in neurology. The Company is developing LEVADEX, an orally inhaled investigational drug for the acute treatment of migraine. The Company has reported positive results from its Phase 3 trial of LEVADEX and has entered into a collaboration agreement with Allergan, Inc. to co-promote LEVADEX to neurologists and pain specialists in the U.S. MAP Pharmaceuticals also applies its proprietary drug particle and inhalation technologies to generate new pipeline opportunities by enhancing the therapeutic benefits of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history.

Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.

Forward-Looking StatementsIn addition to statements of historical facts or statements of current conditions, this press release contains forward-looking statements, including with respect to MAP Pharmaceuticals' LEVADEX product candidate and MAP Pharmaceuticals' expected cash requirements during 2011 describe
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
2. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
3. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
4. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
5. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
6. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
7. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
8. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
9. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
10. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
11. Lotus Pharmaceuticals Announces Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... a leading North American IT solutions and managed services provider, ... Cisco® Partner Summit Country awards. Cisco named ... of the Year for Canada during ... Montreal . "We are thrilled ... this year,s conference," said David MacDonald , Softchoice,s President ...
(Date:5/1/2015)... , May 1, 2015 Albany Molecular ... William S. Marth , AMRI,s President and Chief ... Merrill Lynch 2015 Health Care Conference on Wednesday, May ... live audio webcast of the presentation can be accessed ... The webcast will be archived for ...
(Date:4/30/2015)... Blythewood, South Carolina (PRWEB) May 01, 2015 ... steam system services, is extremely proud to announce that ... have been named as a winner of a Queen’s ... business success for the design and manufacture of a ... is the revolutionary alternative to traditional steam flow ...
(Date:4/30/2015)... South San Francisco, CA (PRWEB) April 30, 2015 ... revenues for the first quarter of 2015 were $4.4 million, ... The net loss for the first quarter was $8.9 ... compared to a net loss for the same period in ... diluted share. As of March 31, 2015, cash, cash equivalents ...
Breaking Biology Technology:Softchoice recognized with two Country Awards at Cisco Partner Summit 2015 2AMRI to Present at the Bank of America Merrill Lynch 2015 Health Care Conference 2Spirax Sarco Receives a Queen’s Award for Innovation 2Spirax Sarco Receives a Queen’s Award for Innovation 3Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 2Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 3Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 4Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 5Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 6Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 7Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 8
... Therapeutics, Inc. today presented final results from its Phase ... of exenatide) for the treatment of type 2 diabetes ... the Study of Diabetes in Vienna, Austria. Results of ... (FPG) within 24 hours of the start of treatment ...
... BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced ... a conference call and webcast on Wednesday, October 28, at ... , , U.S. / Canada Dial-in Number: ... Participant Code: 51404008, Replay ...
... 30 InteKrin Therapeutics Inc. announced today positive results for ... 45th European Association for the Study of Diabetes ... will be presented at 1:45 PM Friday, October 2, 2009 ... His presentation is entitled "Impact of INT131 Besylate, a Selective ...
Cached Biology Technology:Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference 2Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference 3Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference 4Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference 5BioMarin to Host Third Quarter 2009 Financial Results Conference Call and Webcast on Wednesday, October 28 at 5:00 p.m. ET 2InteKrin Therapeutics Presents Positive INT131 Phase 2b Results at the 45th Annual European Association for the Study of Diabetes Meeting 2
(Date:4/14/2015)... OXFORD, Conn. , April 14, 2015 ... "Company"), a biometric authentication company focused on the growing ... has been nominated for the 2015 New York Design ... The Design100, New York City Design Awards are ... are based on over 2,500 ratings from the marketplace, ...
(Date:4/8/2015)...  Infinisource, a leading provider of SaaS-based Human Capital ... leading supplier of biometric identification and security solutions, ... advanced biometrically-enabled time clock, the companies announced today. ... setting a bold, new standard for the collection ... and mid-size employer. When connected to the iSolved ...
(Date:4/2/2015)... -- Fingerprint Cards (FPC) has received an ... distributor World Peace Industrial Group (WPI), part of WPG ... major part of the shipments will take place during ... manufacturers in China . The order ... revenue guidance of + 1 000 MSEK for 2015.  ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2
... with a degree in chemical engineering, was recently elected ... the National Academy of Engineering is among the highest ... honors those who have made outstanding contributions to "engineering ... Space and Missile Systems Center, Air Force Space Command, ...
... Problems related to urination, including incontinence and having to get ... of discussion over recent years. New treatment options have also ... no study has effectively compared the bother of each of ... The FINNO Study is an ongoing questionnaire survey ...
... Ocean to get to the Sargasso Sea to spawn, they swim ... researchers from the University of Southern Denmark report: Even in deep ... is in decline, and all over the world biologists are struggling ... numbers back up. One of the great puzzles is why and ...
Cached Biology News:When you always gotta go… 2Threatened eels disappear in the deep on their way to the Sargasso Sea 2
...
Full-length cDNA 5-PRIME end of clone CS0DE013YM09 of Placenta of Homo sapiens (human). [Source:Uniprot/SPTREMBL;Acc:Q86TS7] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
5(S)-HETE-d8 is used as an internal standard for the quantification of 5(S)-HETE by stable isotope dilution mass spectrometry....
... deuterium atoms at the 9, 10, 12, and ... an internal standard for the quantification of 9(S)-HODE ... by the lipoxygenation of linoleic acid in both ... atherosclerotic plaques, as an esterified component of membrane ...
Biology Products: